Appeal No. 1997-2188
Application 08/137,440
vivo studies were conducted on galanthamine n-butyl carbamate
in mice and yielded "promising results".
Additionally, the examiner has cited several other
references in support of his rejection which acknowledge the
role of AChE inhibitors in treating Alzheimer's disease. See
for example, Robinson et al. at page 1127 wherein the authors
acknowledge the therapeutic effect of AChE inhibitors for
treating Alzheimer's disease. The examiner has also cited
Sarter et al. as evidence that there was a recognition in the
art at the time appellants made their invention that the high
number of failures in clinical trials for drugs ("recognition
enhancers") screened and then tested on an animal model was
directly correlated to the lack of sufficient attention to the
specific psychological mechanisms underlying behavioral
enhancement. Nevertheless, Sarter et al. do recognize at page
154 that, "[a]rguably the strongest case for positive effects
can be made for the AChE inhibitors," and Sarter et al. also
observe at page 149 that:
AChE inhibitors and muscarinic agonists can reverse
behavioral deficits caused by lesions to the cholinergic
basal forebrain nuclei or drug induced AChe depletion in
a wide variety of learning and memory tasks. (citation
omitted)
Further, both Nordberg et al. and Liston et al. recognize the
14
Page: Previous 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next
Last modified: November 3, 2007